Value-based insurance design program in North Carolina increased medication adherence but was not cost neutral

Health Affairs

Volumn 33, Issue 2, 2014, Pages 300-308

  Maciejewski, Matthew L ^a   Wansink, Daryl ^b   Lindquist, Jennifer H ^c   Parker, John C ^d   Farley, Joel F ^e  

^a DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b Blue Cross Blue Shield of North Carolina   (United States)

^c DURHAM VA MEDICAL CENTER   (United States)

^d GLAXOSMITHKLINE   (United States)

^e UNIVERSITY OF NORTH CAROLINA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; GENERIC DRUG; THIAZIDE DIURETIC AGENT;

ANTIHYPERTENSIVE THERAPY; ARTICLE; CONTROLLED STUDY; DISEASE CONTROL; DRUG COST; EMERGENCY CARE; FEMALE; HEALTH CARE COST; HEALTH CARE UTILIZATION; HEALTH INSURANCE; HOSPITAL ADMISSION; HUMAN; HYPERLIPIDEMIA; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; MEDICATION COMPLIANCE; PATIENT COMPLIANCE; UNITED STATES; ADULT; CASE CONTROL STUDY; COST; COST CONTROL; ECONOMICS; INSURANCE; INTERVENTION STUDY; MIDDLE AGED; ORGANIZATION AND MANAGEMENT; PROGRAM EVALUATION; PURCHASING; STATISTICS AND NUMERICAL DATA;

ADULT; CASE-CONTROL STUDIES; COST CONTROL; COST SHARING; FEMALE; HUMANS; INSURANCE CARRIERS; INSURANCE, PHARMACEUTICAL SERVICES; INTERVENTION STUDIES; MALE; MEDICATION ADHERENCE; MIDDLE AGED; NORTH CAROLINA; PROGRAM EVALUATION; VALUE-BASED PURCHASING;

EID: 84893544300     PISSN: 02782715     EISSN: 15445208     Source Type: Journal    
DOI: 10.1377/hlthaff.2013.0260     Document Type: Article

References (49)

1. Hartman M, Martin AB, Benson J, Catlin A, National Health Expenditure Accounts Team. National health spending in 2011: overall growth remains low, but some payers and services show signs of acceleration. Health Aff (Millwood). 2013;32(1): 87-99.
2. Kaiser Family Foundation, Health Research and Education Trust. Employer health benefits: 2012 annual survey. Menlo Park (CA): KFF; 2012.
3. Hajjar I, Kotchen TA. Trends in prevalence, awareness, treatment, and control of hypertension in the United States, 1988-2000. JAMA. 2003;290(2):199-206.
4. Soumerai SB, Pierre-Jacques M, Zhang F, Ross-Degnan D, Adams AS, Gurwitz J, et al. Cost-related medication nonadherence among elderly and disabled Medicare beneficiaries. Arch Intern Med. 2006;166(17): 1829-35.
5. Piette JD, Heisler M, Wagner TH. Cost-related medication underuse among chronically ill adults: the treatments people forgo, how often, and who is at risk. Am J Public Health. 2004;94(10):1782-7.
6. Williams J, Steers WN, Ettner SL, Mangione CM, Duru OK. Costrelated nonadherence by medication type among Medicare Part D beneficiaries with diabetes. Med Care. 2013;51(2):193-8.
7. Goldman DP, Joyce GF, Zheng Y. Prescription drug cost sharing: associations with medication and medical utilization and spending and health. JAMA. 2007;298(1): 61-9.
8. Fendrick AM, Chernew ME. Valuebased insurance design: a "clinically sensitive, fiscally responsible" approach to mitigate the adverse clinical effects of high-deductible consumer-directed health plans. J Gen Intern Med. 2007;22(6):890-1.
9. Fendrick AM, Smith DG, Chernew ME. Applying value-based insurance design to low-value health services. Health Aff (Millwood). 2010;29(11): 2017-21.
10. Chernew ME, Shah MR, Wegh A, Rosenberg SN, Juster IA, Rosen AB, et al. Impact of decreasing copayments on medication adherence within a disease management environment. Health Aff (Millwood). 2008;27(1):103-12.
11. Maciejewski ML, Farley JF, Parker J, Wansink D. Copayment reductions generate greater medication adherence in targeted patients. Health Aff (Millwood). 2010;29(11):2002-8.
12. Choudhry NK, Avorn J, Glynn RJ, Antman EM, Schneeweiss S, Toscano M, et al. Full coverage for preventive medications after myocardial infarction. N Engl J Med. 2011;365(22):2088-97.
13. Berger J. Economic and clinical impact of innovative pharmacy benefit designs in the management of diabetes pharmacotherapy. Am J Manag Care. 2007;13(Suppl 2):S55-8.
14. Zeng F, An JJ, Scully R, Barrington C, Patel BV, Nichol MB. The impact of value-based benefit design on adherence to diabetes medications: a propensity score-weighted difference in difference evaluation. Value Health. 2010;13(6):846-52.
15. Mahoney JJ. Reducing patient drug acquisition costs can lower diabetes health claims. Am J Manag Care. 2005;11(5 Suppl):S170-6.
16. Rodin HA, Heaton AH, Wilson AR, Garrett NA, Plocher DW. Plan designs that encourage the use of generic drugs over brand-name drugs: an analysis of a free generic benefit. Am J Manag Care. 2009;15(12): 881-8.
17. Kelly EJ, Turner CD, Frech-Tamas FH, Doyle JJ, Mauceri EG. Valuebased benefit design and healthcare utilization in asthma, hypertension, and diabetes. Am J Pharm Benefits. 2009;1(4):217-21.
18. Chang A, Liberman JN, Coulen C, Berger JE, Brennan TA. Value-based insurance design and antidiabetic medication adherence. Am J Pharm Benefits. 2010;2(1):39-44.
19. Choudhry NK, Fischer MA, Avorn J, Schneeweiss S, Solomon DH, Berman C, et al. At Pitney Bowes, value-based insurance design cut copayments and increased drug adherence. Health Aff (Millwood). 2010;29(11):1995-2001.
20. Chernew ME, Juster IA, Shah M, Wegh A, Rosenberg S, Rosen AB, et al. Evidence that value-based insurance can be effective. Health Aff (Millwood). 2010;29(3):530-6.
21. Gibson TB, Mahoney J, Ranghell K, Cherney BJ, McElwee N. Value-based insurance plus disease management increased medication use and produced savings. Health Aff (Millwood). 2011;30(1):100-8.
22. Gibson TB, Wang S, Kelly E, Brown C, Turner C, Frech-Tamas F, et al. A value-based insurance design program at a large company boosted medication adherence for employees with chronic illnesses. Health Aff (Millwood). 2011;30(1):109-17.
23. Choudhry NK, Fischer MA, Avorn JL, Lee JL, Schneeweiss S, Solomon DH, et al. The impact of reducing cardiovascular medication copayments on health spending and resource utilization. J Am Coll Cardiol. 2012; 60(18):1817-24.
24. Frank MB, Fendrick AM, He Y, Zbrozek A, Holtz N, Leung S, et al. The effect of a large regional health plan's value-based insurance design program on statin use. Med Care. 2012;50(11):934-9.
25. Farley JF, Wansink D, Lindquist J, Parker J, Maciejewski ML. Medication adherence changes following value-based insurance design. Am J Manag Care. 2012;18(5):265-74.
26. Fairman KA, Curtiss FR.What do we really know about VBID? Quality of the evidence and ethical considerations for health plan sponsors. J Manag Care Pharm. 2011;17(2): 156-74.
27. Keenan NL, Rosendorf KA. Prevalence of hypertension and controlled hypertension-United States, 2005-2008. MMWR Surveill Summ. 2011; 60(Suppl):94-7.
28. Hoyert DL, Xu J. Deaths: preliminary data for 2011. Natl Vital Stat Rep. 2012;61(6):1-51.
29. Roger VL, Go AS, Lloyd-Jones DM, Benjamin EJ, Berry JD, Borden WB, et al. Heart disease and stroke statistics- 2012 update: a report from the American Heart Association. Circulation. 2012;125(1):e2-220.
30. Go AS, Mozaffarian D, Roger VL, Benjamin EJ, Berry JD, Borden WB, et al. Heart disease and stroke statistics- 2013 update: a report from the American Heart Association. Circulation. 2013;127(1):e6-245.
31. Davis KE (Commonwealth Fund, New York, NY). Expenditures for hypertension among adults age 18 and older, 2010: estimates for the U.S. civilian noninstitutionalized population [Internet]. Rockville (MD): Agency for Healthcare Research and Quality; 2013 Apr [cited 2013 Dec 23]. (Statistical Brief No. 404). Available from: http:// meps.ahrq.gov/mepsweb/data_ files/publications/st404/stat404 .shtml
32. Optuminsight. Transparency: measuring and improving the quality and efficiency of health care [Internet]. Eden Prairie (MN): Optuminsight; [cited 2013 Dec 23]. Available from: http://www.optumin sight.com/transparency/etg-links/
33. To access the Appendix, click on the Appendix link in the box to the right of the article online.
34. Parsons LS. Reducing bias in a propensity score matched-pair sample using GREEDY matching techniques. In: SUGI 26 proceedings [Internet]. Cary (NC): SAS; [cited 2013 Dec 23]. Available from: http:// www2.sas.com/proceedings/ sugi26/p214-26.pdf
35. Austin PC. Statistical criteria for selecting the optimal number of untreated subjects matched to each treated subject when using many-toone matching on the propensity score. Am J Epidemiol. 2010;172(9): 1092-7.
36. Roebuck MC, Liberman JN, Gemmill-Toyama M, Brennan TA. Medication adherence leads to lower health care use and costs despite increased drug spending. Health Aff (Millwood). 2011;30(1):91-9.
37. Altman DG, Bland JM. Absence of evidence is not evidence of absence BMJ. 1995;311(7003):485.
38. Chernew ME, Baicker K, Hsu J. The specter of financial armageddon- health care and federal debt in the United States. N Engl J Med. 2010; 362(13):1166-8.
39. Fuchs VR. Health care is different- that's why expenditures matter. JAMA. 2010;303(18):1859-60.
40. Choudhry NK, Rosenthal MB, Milstein A. Assessing the evidence for value-based insurance design. Health Aff (Millwood). 2010;29(11): 1988-94.
41. Aetna. Hartford (CT): Aetna; c2001-14 [Internet]. Press release, Aetna launching value-based program that improves medication adherence, cost and outcomes for members who have suffered from heart attacks; 2011 Nov 14 [cited 2013 Dec 23]. Available from: http://www.aetna .com/news/newsReleases/2011/ 1114-AetnaRx-HealthyOutcomes .html
42. Lee JL, Maciejewski ML, Raju SS, Shrank WH, Choudhry NK. Valuebased insurance design: quality improvement but no cost savings. Health Aff (Millwood). 2013;32(7): 1251-7.
43. Department of Health and Human Services. What are my preventive care benefits? [Internet]. Washington (DC): HHS; [cited 2014 Jan 3]. Available from: https://www.health care.gov/what-are-my-preventivecare-benefits/
44. Meeker D, Joyce GF, Malkin J, Teutsch SM, Haddix AC, Goldman DP. Coverage and preventive screening. Health Serv Res. 2011; 6(1 Pt 1):173-84.
45. Goodwin SM, Anderson GF. Effect of cost-sharing reductions on preventive service use among Medicare feefor-service beneficiaries. Medicare Medicaid Res Rev. 2012;2(1):E1-25.
46. Department of Labor. FAQs about Affordable Care Act implementation part V and mental health parity implementation [Internet]. Washington (DC): DOL; [cited 2013 Dec 23]. Available from: http:// www.dol.gov/ebsa/faqs/faq-aca5 .html
47. Medicare Payment Advisory Commission. Report to the Congress: Medicare and the health care delivery system [Internet]. Washington (DC): MedPAC; 2011 Jun [cited 2013 Dec 23]. Available from: http:// www.medpac.gov/documents/ jun11_entirereport.pdf
48. Centers for Medicare and Medicaid Services. Medicaid and Children's Health Insurance Programs: essential health benefits in alternative benefit plans, eligibility notices, fair hearing and appeal processes, and premiums and cost sharing; exchanges: eligibility and enrollment. Fed Regist. 2013;78(135):42159-322.
49. Buttorff C, Tunis SR, Weiner JP. Encouraging value-based insurance designs in state health insurance exchanges. Am J Manag Care. 2013;19(7):593-600.